Table I.
Variables | N (%) |
---|---|
N | 33 |
Median age, years (range) | 62 (27 – 83) |
Sex | |
Female | 9 (27) |
Male | 24 (73) |
Karnofsky performance score | |
70 | 5 (15) |
80–100 | 28 (85) |
Diagnosis | |
PTCL-NOS | 21 (64) |
AITL | 8 (24) |
ALCL, T- and null cell types | 4 (12) |
Ann Arbor Stage | |
II | 4 (12) |
III | 9 (27) |
IV | 20 (61) |
B symptoms | |
No | 18 (55) |
Yes | 15 (45) |
IPI Score | |
Low | 9 (27) |
Low – intermediate | 9 (27) |
High – intermediate | 9 (27) |
High | 6 (19) |
Lactate dehydrogenase | |
Normal | 17 (52) |
Elevated | 16 (48) |
Extranodal involvement | |
0–1 | 24 (73) |
2 or more | 9 (27) |
Median number of chemotherapy cycles (range) | 4 (1–6) |
Median follow-up of survivors, months (range) | 20.4 (11.9 – 31.2) |
PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; IPI, International Prognostic Index.